IMU and UK Biobank to generate the world’s most detailed, large-scale picture of the human immune system for advancing research into health and disease

IMU is collaborating with UK Biobank, Waters Corporation and Ultima Genomics to profile blood samples from an initial cohort of 80,000 UK Biobank blood samples

IMU will generate more than 100 million immune data points from each sample to create the largest, most detailed immune dataset assembled to date

The study will add a high-resolution immune profiling layer to UK Biobank's existing de-identified genomic, imaging, clinical and lifestyle data to enable a better understanding of how immune variation relates to disease risk, progression, treatment response and long-term health outcomes

LONDON, October 19, 2026--IMU Biosciences ('IMU or the 'Company'), a biotechnology company using its High Definition Immunology™ platform to better understand the immune system and drive a shift in how we understand, diagnose, and treat disease, has today announced a new collaboration with UK Biobank to generate large-scale multi-omic immune profiling data from 80,000 blood samples collected from UK Biobank participants.

The project will use IMU's HD Immunology™ platform in conjunction with Waters Corporation's flow cytometry and multi-omic instrumentation as part of the strategic partnership announced in June. Ultima Genomics' ('Ultima') recently launched UG200 Sequencing Platform will produce the project's readouts, providing the magnitude and economics for large scale omics data generation, complementing Ultima's existing work as part of UK Biobank Pharma Proteomics Project. By integrating high-dimensional immune-cell profiling, transcriptomic analysis and AI-based computational methods, the study aims to create the most detailed large-scale picture of the human immune system ever seen.

UK Biobank is the world's most comprehensive source of biomedical data for health research in the public interest. Its dataset includes de-identified biological, clinical, imaging and lifestyle data collected from 500,000 volunteers over the last 15 years and continues to grow. In line with UK Biobank's established access procedures, data generated through the study will, over time, be returned to UK Biobank and made available to approved researchers. This will add a new immune profiling layer to an established international research resource.

IMU is building a high-resolution immune dataset designed to connect individual immune profiles with large-scale clinical data. In the first phase of the study, IMU will apply its high-throughput immune profiling platform to blood samples from over 80,000 UK Biobank blood samples, with the ambition to expand across the full UK Biobank cohort of 500,000 participants.